Randomized Controlled Trial of Treating Rectal Hypersensitivity - Comparing Escitalopram With Sensory Adaptation Training



Status:Active, not recruiting
Conditions:Constipation, Irritable Bowel Syndrome (IBS), Neurology
Therapuetic Areas:Gastroenterology, Neurology
Healthy:No
Age Range:18 - Any
Updated:7/25/2018
Start Date:December 2007
End Date:December 2018

Use our guide to learn which trials are right for you!

Constipation is a common digestive disorder. After excluding dietary factors, drugs and other
secondary causes, at least three broad pathophysiologic subtypes are recognized- dyssynergic
defecation, constipation-predominant irritable bowel syndrome (IBS-C) and slow transit
constipation (STC), all predominantly affect women and elderly. Many patients also
demonstrate abnormal rectal perception with both rectal hyposensitivity and hypersensitivity
being common. Recent surveys show that most constipated patients are dissatisfied with
current therapy. Also, constipated patients showed significant psychological dysfunction and
impaired quality of life. OBJECTIVE: To investigate a novel biofeedback technique of
improving rectal hypersensitivity.

METHODS: A large compliant balloon attached to a barostat was placed in the rectum in 8
patients with rectal hypersensitivity (urgency/pain threshold <30 mm Hg). Sensory
deconditioning was performed by incremental balloon distensions (1-2 mmHg) until normal
thresholds were reached.

To investigate a novel biofeedback technique of improving rectal hypersensitivity using
rectal barostat and to compare this with clinical standard of care comprising of low dose
antidepressant therapy with escitalopram. Patients will be randomized to sensory adaptation
training or escitalopram in a 1:1 ratio

Inclusion Criteria:

All patients must fulfill the diagnostic criteria for IBS-C (Rome III) as defined below and
have rectal hypersensitivity (see below).

- Patients must report recurrent abdominal pain or discomfort for at least 3 days per
month in the last 3 months with two or more of the following symptoms:

- Improvement with defecation; and/or

- Onset associated with a change in frequency of stool; and/or

- Onset associated with a change in form (appearance) of stool

- No structural diseases

- On a diary:

- Pain/discomfort for at least 2 days/week;

- No loose or watery stool <25% of bowel movements.

Exclusion Criteria:

- Patients with mixed-IBS.

- Patients currently on SSRI or MAO inhibitors. Patients on stable doses of other
antidepressants will be included provided the dose is unchanged during study.

- Patients taking drugs that are constipating, (e.g.; calcium channel antagonists will
either be excluded or drug discontinued)

- Patients with co-morbid illnesses; severe cardiac disease, chronic renal failure or
previous gastrointestinal surgery except cholecystectomy and appendectomy.

- Neurologic diseases e.g.; head injury, epilepsy, multiple sclerosis, strokes, spinal
cord injuries.

- Impaired cognizance (mini mental score of < 15) and/or legally blind.

- Pregnant or likely to conceive during the course of the study. Women with potential
for pregnancy must be willing to use contraceptive measures during the study. Urinary
pregnancy tests will be performed on such women prior to any radiologic procedures.

- Hirschsprung's disease.

- Alternating constipation and diarrhea (22).

- Ulcerative/Crohns colitis.

- Previous pelvic surgery, rectocele/bladder repair, radical hysterectomy, anal surgery.

- Rectal prolapse or anal fissure.
We found this trial at
1
site
200 Hawkins Dr,
Iowa City, Iowa 52242
866-452-8507
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials